Yumeng Hu

Yumeng Hu

Auto-generated profile, based on publicly available information

Yumeng Hu

Chinese Academy of Medical Sciences & Peking Union Medical College 1 State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Beijing, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2026 in Cancer Research
Verified
Journal Article
Open access
SZShaobo Zhang
Shaobo Zhang
HYHao Yuan
Hao Yuan
MGMuzi Guo
Muzi Guo
ZZZhijun Zhou
Zhijun Zhou
YHYumeng Hu
Yumeng Hu
MLMingyang Liu
Mingyang Liu
Pancreatic cancer remains one of the deadliest malignancies, with gemcitabine-based chemotherapy as the mainstay treatment for most patients, yet resistance emerges almost universally. A defining feature of pancreatic cancer is its dense, fibroblast-rich stroma, in which heterogeneous cancer-associated fibroblasts (CAF) actively shape tumor biology and therapeutic response. Here, we elucidated a stromal–metabolic mechanism through which chemoresistant CAFs confer gemcitabine resistance. We identified a subset of mitophagy-competent CAFs that enhanced pancreatic cancer gemcitabine resistance. The epithelial–mesenchymal transition transcription factor ZEB1 acts as a master regulator of this CAF-driven chemoresistance program, being upregulated and epigenetically activated via SETD1A-mediated H3K4 methylation in gemcitabine-resistant CAFs. ZEB1 promotes BNIP3-mediated mitophagy in CAFs, leading to increased nucleotides secretion, which competitively inhibited gemcitabine incorporation into cancer cells while simultaneously supplying pyrimidine metabolism substrates for pyrimidine metabolism. Concurrently, ZEB1 transcriptionally activated CXCL8, engaging the CXCR1/2–MEK/ERK pathway in tumor cells and further augmenting pyrimidine metabolism via the RRM1/E2F1/G6PD axis, collectively diminishing gemcitabine cytotoxicity. Notably, combined inhibition of CXCR1/2 or G6PD with gemcitabine robustly suppressed tumor growth and restored chemosensitivity both in vitro and in vivo. These findings uncover a key stromal–metabolic axis in pancreatic cancer, linking mitophagy CAF activity to metabolic remodeling in tumor cells and identifying ZEB1 and its downstream network as actionable targets to overcome chemoresistance. Significance: This study reveals that ZEB1 reprograms mitophagy-competent CAFs to promote gemcitabine resistance by enhancing nucleotide supply and activating tumor pyrimidine metabolism, supporting therapeutic targeting of the ZEB1–CXCL8–pyrimidine axis in pancreatic cancer.

14 August 2026
Verified
Other
Open access
SZShaobo Zhang
Shaobo Zhang
HYHao Yuan
Hao Yuan
MGMuzi Guo
Muzi Guo
ZZZhijun Zhou
Zhijun Zhou
YHYumeng Hu
Yumeng Hu
MLMingyang Liu
Mingyang Liu
Pancreatic cancer remains one of the deadliest malignancies, with gemcitabine-based chemotherapy as the mainstay treatment for most patients, yet resistance emerges almost universally. A defining feature of pancreatic cancer is its dense, fibroblast-rich stroma, in which heterogeneous cancer-associated fibroblasts (CAF) actively shape tumor biology and therapeutic response. Here, we elucidated a stromal–metabolic mechanism through which chemoresistant CAFs confer gemcitabine resistance. We identified a subset of mitophagy-competent CAFs that enhanced pancreatic cancer gemcitabine resistance. The epithelial–mesenchymal transition transcription factor ZEB1 acts as a master regulator of this CAF-driven chemoresistance program, being upregulated and epigenetically activated via SETD1A-mediated H3K4 methylation in gemcitabine-resistant CAFs. ZEB1 promotes BNIP3-mediated mitophagy in CAFs, leading to increased nucleotides secretion, which competitively inhibited gemcitabine incorporation into cancer cells while simultaneously supplying pyrimidine metabolism substrates for pyrimidine metabolism. Concurrently, ZEB1 transcriptionally activated CXCL8, engaging the CXCR1/2–MEK/ERK pathway in tumor cells and further augmenting pyrimidine metabolism via the RRM1/E2F1/G6PD axis, collectively diminishing gemcitabine cytotoxicity. Notably, combined inhibition of CXCR1/2 or G6PD with gemcitabine robustly suppressed tumor growth and restored chemosensitivity both in vitro and in vivo. These findings uncover a key stromal–metabolic axis in pancreatic cancer, linking mitophagy CAF activity to metabolic remodeling in tumor cells and identifying ZEB1 and its downstream network as actionable targets to overcome chemoresistance. Significance:ZEB1 reprograms mitophagy-competent CAFs to promote gemcitabine resistance by enhancing nucleotide supply and activating tumor pyrimidine metabolism, supporting therapeutic targeting of the ZEB1–CXCL8–pyrimidine axis in pancreatic cancer.

14 August 2026
Verified
Other
Open access
PDF file
SZShaobo Zhang
Shaobo Zhang
HYHao Yuan
Hao Yuan
MGMuzi Guo
Muzi Guo
ZZZhijun Zhou
Zhijun Zhou
YHYumeng Hu
Yumeng Hu
MLMingyang Liu
Mingyang Liu
Blocking of ZEB1 in CAFs suppresses nucleoside metabolism in PC

14 August 2026
Verified
Other
Open access
PDF file
SZShaobo Zhang
Shaobo Zhang
HYHao Yuan
Hao Yuan
MGMuzi Guo
Muzi Guo
ZZZhijun Zhou
Zhijun Zhou
YHYumeng Hu
Yumeng Hu
MLMingyang Liu
Mingyang Liu
ZEB1 enhances CAF mitophagy via BNIP3 which leads to GEM resistance in PC

14 August 2026
Verified
Other
Open access
PDF file
SZShaobo Zhang
Shaobo Zhang
HYHao Yuan
Hao Yuan
MGMuzi Guo
Muzi Guo
ZZZhijun Zhou
Zhijun Zhou
YHYumeng Hu
Yumeng Hu
MLMingyang Liu
Mingyang Liu
ZEB1 facilitates autophagy of CAFs and blocking ZEB1 increased PC GEM sensitivity

14 August 2026
Verified
Other
Open access
PDF file
SZShaobo Zhang
Shaobo Zhang
HYHao Yuan
Hao Yuan
MGMuzi Guo
Muzi Guo
ZZZhijun Zhou
Zhijun Zhou
YHYumeng Hu
Yumeng Hu
MLMingyang Liu
Mingyang Liu
CAFs-derived CXCL8 upregulates RRM1-E2F1-G6PD through MAPK pathway in pancreatic cancer